Sign up


Match Document Document Title
8609101 Granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibodies  
The invention provides a GM-CSF neutralizing human monoclonal antibody, 1783J22, as well as methods of making and use thereof. The monoclonal antibody is further characterized by its ability to...
8609111 Antibodies against clostridium difficile toxins and uses thereof  
Antibodies that specifically bind to toxins of C. difficile, antigen binding portions thereof, and methods of making and using the antibodies and antigen binding portions thereof are provided herein.
8603474 Membrane transporter NaPi2b (SCL34A1) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy  
The present disclosure relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide...
8603465 Methods for treatment of polyposis  
The present invention relates to method for treating medical disorders mediated by mutations in the APC gene by administering an IGF1R inhibitor. Such disorders include, for example, familial...
8603480 Human cytomegalovirus neutralizing antibodies and use thereof  
The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a...
8603469 Methods of treating cancer with human monoclonal antibodies against interleukin 8  
Isolated human monoclonal antibodies which bind to IL-8 (e.g., human IL-8) are disclosed. The human antibodies can be produced in a hybridoma, transfectoma or in a non-human transgenic animal,...
8603468 Neutralization of HCV  
Aspects of the present invention concern compositions that induce and/or improve an immune response to hepatitis C virus (HCV). Methods of making and using compositions that include epitopes of the...
8603470 Use of IL-20 antagonists for treating liver diseases  
Reducing liver fibrosis in a subject having or being suspected of having a liver disease using an IL-20 antagonist, which can be an antibody that blocks a signaling pathway mediated by IL-20. Such...
8603467 Monoclonal antibodies binding to avian influenza virus subtype H5 haemagglutinin and uses thereof  
The present invention provides monoclonal antibodies that bind specifically to H5 subtype avian influenza virus hemagglutinin (HA) proteins, and can block the binding activity of at least 50% of...
8603466 Agonist antibodies against TSHR  
The invention provides antibodies that bind the thyroid stimulating hormone receptor (TSHR), especially in humans, and their uses in diagnostic and therapeutic roles. The invention also provides...
8603485 Bystander immune suppression as a predictor for response to a vaccine  
The present invention relates to antigen-specific immune regulatory response. Methods for detecting an antigen-specific immune regulatory response, methods for selecting candidate vaccine...
8603481 Therapeutic agents for solid tumors  
A therapeutic agent for solid tumors, the agent comprising as an active ingredient, an antibody that specifically binds to a protein having the amino acid sequence represented by SEQ ID NO:2 or an...
8604169 Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer  
A novel gene 251P5G2 and its encoded protein, and variants thereof, are described wherein 251P5G2 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the...
8597643 Antibodies for binding to non-functional P2X7 receptors in trimeric form  
The invention relates to the identification of a novel epitope on non-functional P2X7 receptors which are implicated in cancer. The epitope includes a region from two adjacent monomers within the...
8598137 Use of SAM68 for modulating signaling through the TNF receptor  
Sam68 plays a role in TNF-dependent signaling, including NF-kB signaling and extrinsic activation of apoptosis. In some embodiments, inhibitors of Sam68 are administered to inhibit TNF-dependent...
8597649 Antagonist antibodies directed against calcitonin gene-related peptide and methods using same  
The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot...
8597898 Fusion polypeptides capable of activating receptors  
A fusion polypeptide comprising (A)x-M-(A′)y, wherein A and A′ are each polypeptides capable of binding a target receptor. The fusion polypeptides of the invention form multimeric proteins whi...
8597654 Adjuvant therapy with an anti-ERBB2 antibody conjugated to a maytansiniod  
The present application describes adjuvant therapy of nonmetastatic breast cancer using an anti-ErbB2 antibody conjugated to a maytansinoid.
8597648 Fully human anti-TNF-alpha monoclonal antibody, preparation method and use thereof  
The present invention provides a full human anti-TNF-α monoclonal antibody, the preparation method and use thereof. The antibody in the present invention has an amino acid sequence of heavy chain ...
8597650 Methods for treating rheumatoid arthritis with anti-bile salt-stimulated lipase (BSSL) antibodies  
It provides methods and pharmaceutical compositions comprising antagonists to the protein Bile Salt-Stimulated Lipase (BSSL) for the prevention, prophylaxis and treatment of inflammatory diseases,...
8598321 Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins  
This invention provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The...
8597636 Method for treating autoimmune diseases and compositions therefor  
A method of cell-based therapy for treating an autoimmune disease is disclosed. The method is directed at stimulating leukocytes and/or dendritic cells to interrupt autoimmunity in a host. The...
8597899 Method for automated tissue analysis  
The invention provides an improved method for identifying and interpreting tissue specimens and/or cells derived from tissue specimens. A panel of cell-based reagents provides a number of readouts...
8598322 Anti CEACAM1 antibodies and methods of using same  
A hybridoma cell which has been deposited under ATCC Accession Number PTA-9974 is disclosed. Also provided are Antibodies and methods of using same.
8591890 Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality  
The present invention relates to methods of improving a treatment outcome comprising administering a heat shock protein (HSP) preparation or an α-2-macroglobulin (α2M) preparation with a n...
8591900 Anti-CD40 antibodies  
The present invention relates to new humanized antagonistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same.
8591892 FTY720 increases CD74 expression and sensitizes cancer cells to anti-CD74 antibody-mediated cell death  
Disclosed herein are methods and compositions comprising fingolimod and anti-CD74 antibodies or fragments thereof. In preferred embodiments, the fingolimod increases the expression of CD74 in...
8591887 EPHA2 as a therapeutic target for cancer  
The present invention is directed to compounds and methods for the treatment of metastatic disease. The compounds of this invention have specificity for EphA2, an epithelial cell tyrosine kinase...
8591891 Monoclonal antibodies against ANGPTL4  
Monoclonal antibodies that specifically bind to ANGPTL4 are provided. Monoclonal antibodies that neutralize at least one activity of ANGPTL4 are provided. Methods of treating a disorder of lipid...
8591897 Anti-ERBB2 antibody adjuvant therapy  
The present application describes adjuvant therapy of nonmetastatic breast cancer using HERCEPTIN®.
8591889 Human monoclonal antibodies specific for CD22  
Disclosed herein are isolated human monoclonal antibodies that specifically bind human CD22 with a dissociation constant (Kd) of 25 nM or less. Nucleic acids encoding these antibodies, expression...
8591898 Treatment of interstitial cystitis  
The present invention relates to the use of an anti-NGF antibody in the treatment or prevention of pain and/or a lower urinary tract symptom (LUTS) associated with interstitial cystitis and/or...
8591885 Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems  
Biocompatible intraocular drug delivery systems include a carbonic anhydrase inhibitor therapeutic agent and a polymeric component in the form of an implant, a microparticle, a plurality of...
8591886 Combination therapies employing GITR binding molecules  
The present invention provides combination therapies that employ a GITR binding molecule in combination with one or more additional agents.
8592163 Method of determining immune enhancement of virus infectivity using Fc receptor-transfected cell lines  
The present invention relates to a method of detecting immune enhancement of virus infectivity, a method of determining neutralization and immune enhancement of virus infectivity, a method of...
8591903 Inhibition of TACE or amphiregulin for the modulation of EGF receptor signal transactivation  
The present invention relates to the modulation of transactivation of receptor tyrosine kinases by G protein or G protein-coupled receptor (GPCR) mediated signal transduction in a cell or an...
8591888 Cadherin-11 EC1 domain antagonists for treating inflammatory joint disorders  
The present invention relates to Cadherin-11 antagonists and compositions comprising Cadherin-11 antagonists. The invention also relates to methods for treating inflammatory joint disorders, such...
8586041 Human monoclonal antibodies to epidermal growth factor receptor (EGFR)  
Isolated human monoclonal antibodies which specifically bind to human EGFR, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a...
8586033 Integrin αIIbβ3 specific antibodies and peptides  
The present invention provides integrin αIIbβ3 specific antibodies and peptides. The antibodies and peptides demonstrate little or no immunoreactivity with other integrins. Methods for inhibiting p...
8586531 Erythropoietin immunoglobulin fusion proteins  
Disclosed are fusion proteins comprising a biologically active molecule and an immunoglobulin (Ig) Fc domain which is linked to the biologically active molecule. The Fc domain is a hybrid human Fc...
8586044 Treatment of chronic pelvic pain syndrome  
The present invention provides compositions and methods for detection, diagnosis, treatment and/or prevention of chronic pelvic pain syndrome. In particular, the present invention provides...
8586038 Chimeric immunoglobulin fusion proteins  
Disclosed are fusion proteins comprising a biologically active molecule and an immunoglobulin (Ig) Fc domain which is linked to the biologically active molecule. The Fc domain is a hybrid human Fc...
8586713 Readily isolated bispecific antibodies with native immunoglobulin format  
A bispecific antibody format providing ease of isolation is provided, comprising immunoglobulin heavy chain variable domains that are differentially modified in the CH3 domain, wherein the...
8586045 Methods of using anti-CGRP antagonist antibodies  
The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot...
8586043 Methods for treating breast cancer with inhibitors of neurotensin activation of NTSR1  
The present invention relates to methods for the treatment, the prognostic assessment and the detection of breast cancer.
8586037 Antibodies against IL-17BR  
The invention provides the antibody D9.2 and antibody molecules based on D9.2 which bind interleukin-17 receptor B. These may be useful in therapy, e.g. the treatment of asthma, ulcerative colitis...
8586036 Methods for the treatment of IL-1β related diseases  
Disclosed are methods for the treatment and/or prevention of Type 2 diabetes, insulin resistance and disease states and conditions characterized by insulin resistance, obesity, hyperglycemia,...
8586716 EPHB3-specific antibody and uses thereof  
EphB3-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating cancer.
8586035 Use of IL-23 antagonists for treatment of infection  
Methods and compositions comprising antagonists of IL-23 are provided for the treatment of infections, such as chronic bacterial, viral and fungal infections.
8586034 Cytomegalovirus disintegrin-like peptides  
The present invention relates to methods and compositions for inhibiting the entry of viruses, such as herpesviruses into a host cell. A conserved viral integrin-binding gB disintegrin-like domain...